Skip to content

Posts from the ‘Q&As’ Category

Q&A: Research on the wards

Chris Lerpiniere*

Chris Lerpiniere*

We know that clinical research relies on doctors and willing patients, but what about nurses? Chris Lerpiniere is a Senior Research Nurse on the MRC-funded RUSH, ‘Research to Understand Stroke due to Haemorrhage’ project at the University of Edinburgh. Here she tells Hazel Lambert about her work, and the route she took from clinical nursing to research.

How did you become a research nurse?

My nursing experience has been within neurosciences, critical care and tissue donation for transplant. Research has always been something I have had an interest in, particularly when you see the benefits and improvement to patient care brought about by research. However my career had followed a more clinical-based route until I saw the advert for the RUSH research nurse post and realised it was an opportunity to branch out into research.

What is the RUSH study aiming to do?

There are two types of stroke: one is caused by blockages in the blood supply to the brain (ischaemic), and the other is caused by bleeding in the brain (haemorrhagic). RUSH looks at what causes haemorrhagic strokes and the best way of treating them. I work on a part of the programme called the LINCHPIN (Lothian study of INtraCerebral Haemorrhage, Pathology, Imaging and Neurological outcome). Read more

Painless: a Q&A with Geoff Woods

Geoff Woods*

Geoff Woods*

How can studying rare diseases help those with more common conditions? To mark Rare Disease Day, Ellen Charman speaks to Professor Geoff Woods about how his discovery in Pakistan of a disease in which people don’t feel pain could lead to treatments for those who experience too much.

Can you tell me about this condition, congenital analgesia?

I first came across the condition when I was in Pakistan researching encephalopathy (diseases of the brain) and I was asked to see a boy who reportedly did not feel any pain. He was doing street theatre to earn money walking across hot coals and putting daggers in his arms, and then going to the local children’s hospital to get patched up. Sadly, before I got the chance to see him, he’d jumped from a roof to amuse friends and walked away from it, but later died from a bleed in the brain.

When I came back to the UK, I asked around and found two families also affected by the condition. At first, due to the common inclination towards risky and dangerous activities, I assumed that those with the condition had a degree of intellectual disability; however, I later found their development to be normal, but without the sense of pain to modulate their behaviour.  Read more

Rising to the global challenge

Mark Palmer

Mark Palmer

Tackling health problems around the world demands a global response. With a 100-year history of strategic international collaboration, MRC scientists today collaborate with researchers in more than 100 countries. Dr Mark Palmer, MRC Director of International Strategy, talks to Isabel Baker about the changing landscape of international collaboration and the exciting new opportunities it has to offer.


Has MRC-funded research always been international?

Yes, science is global, it’s an international activity. There has always been the exchange of ideas between people working in science, and these shared ideas spark new innovations and understanding. Science is about trying to progress knowledge. Increasingly, pooling resources allows us to solve problems that we couldn’t tackle alone.

Why collaborate on an international scale?

Firstly, health and diseases don’t recognise borders. Pandemic infections, for example, can only be tackled by taking a global approach. For many diseases it is also essential that research is conducted in those countries where the disease is prevalent. Secondly, many clinical studies may need large cohorts of patients; in particular when the disease is rare, research cannot be conducted in one country alone. Additionally, international collaboration can give researchers the chance to work in a different political, regulatory or intellectual environment where different approaches have been made to problem solving. Exposure to a different way of thinking, and seeing how other people work, can be hugely beneficial to progressing research in our own country. Read more